(Q34631934)

English

A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols).

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols). (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

0 references

multiple sclerosis

0 references

1 reference

based on heuristic

inferred from title

author name string

W Notcutt

1

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

R Langford

2

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

P Davies

3

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

S Ratcliffe

4

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

R Potts

5

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

publication date

30 August 2011

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Multiple Sclerosis Journal

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

18

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

219-228

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Prevalence and treatment of spasticity reported by multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1177%2F1352458511419700

21 January 2018

Regional variations in the prevalence of multiple sclerosis in French farmers

1 reference

https://api.crossref.org/works/10.1177%2F1352458511419700

21 January 2018

The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage

1 reference

https://api.crossref.org/works/10.1177%2F1352458511419700

21 January 2018

High-dose oral baclofen: experience in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458511419700

21 January 2018

Treatments for spasticity and pain in multiple sclerosis: a systematic review

1 reference

https://api.crossref.org/works/10.1177%2F1352458511419700

21 January 2018

Spasticity: clinical perceptions, neurological realities and meaningful measurement

1 reference

https://api.crossref.org/works/10.1177%2F1352458511419700

21 January 2018

Biomechanical approaches applied to the lower and upper limb for the measurement of spasticity: a systematic review of the literature.

1 reference

https://api.crossref.org/works/10.1177%2F1352458511419700

21 January 2018

Cannabinoids control spasticity and tremor in a multiple sclerosis model

1 reference

https://api.crossref.org/works/10.1177%2F1352458511419700

21 January 2018

Pharmacology of cannabinoid CB1 and CB2 receptors.

1 reference

https://api.crossref.org/works/10.1177%2F1352458511419700

21 January 2018

Neuropharmacology and therapeutic potential of cannabinoids

1 reference

https://api.crossref.org/works/10.1177%2F1352458511419700

21 January 2018

Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects

1 reference

https://api.crossref.org/works/10.1177%2F1352458511419700

21 January 2018

Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients

1 reference

https://api.crossref.org/works/10.1177%2F1352458511419700

21 January 2018

Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458511419700

21 January 2018

Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1177%2F1352458511419700

21 January 2018

Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458511419700

21 January 2018

The effect of treatment expectation on drug efficacy: imaging the analgesic benefit of the opioid remifentanil

1 reference

https://api.crossref.org/works/10.1177%2F1352458511419700

21 January 2018

The cannabis withdrawal syndrome

1 reference

https://api.crossref.org/works/10.1177%2F1352458511419700

21 January 2018

A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458511419700

21 January 2018

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1177%2F1352458511419700

21 January 2018

Identifiers

10.1177/1352458511419700

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34631934&oldid=1532446416"